TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1978069
Drug: Nimodipine 120
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine 120 mg per day
Study: 69882
Drug: Monoamine-oxidase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoamine-oxidase inhibitors (clorgyline and pargyline)
Study: 31407967
Drug: Clinical model
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical model using predictors (clinical stage N2 or N3, presence of axillary lymphadenopathy at US after NAC, tumor size reduction less than 50% at MRI, Ki‐67 negativity, hormone receptor positivity, and HER2 negativity)
Study: 26005768
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment in the municipality (control group)
Study: 329848
Drug: Glycopyrrolate 0.2
Normalized name: glycopyrrolate 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 0.2 mg + Neostigmine 1.0 mg
Study: 329848
Drug: Atropine +
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine + Neostigmine (exact dosage not specified)
Study: 27838943
Drug: Betamethasone (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (two consecutive doses of 12 mg intramuscularly, 24 hours apart)
Study: 25459995
Drug: Probiotic strains
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic strains (Bifidobacterium longum, B. lactis, Lactobacillus acidophilus, L. rhamnosus, L. plantarum, and Pediococcus pentosaceus) at a dose of 10^9 colony forming units/g, administered twice daily for 1 week.
Study: 25459995
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered twice daily for 1 week.
Study: 23787721
Drug: Valsartan and
Normalized name: valsartan and aliskiren
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan and an ACE inhibitor (dual RAAS blockade)
Study: 8659771
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol (150 mg)
Study: 8659771
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (2 mg bolus + 0.2 mg/h continuous infusion)
Study: 30389347
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for insomnia (CBT-I) combined with the modern neuroscience approach
Study: 29171486
Drug: Cerebrolysin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin treatment
Study: 19155895
Drug: Oral sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sedation (10 mg of oxycodone and 1 mg of lorazepam)
Study: 19155895
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation (100 micrograms fentanyl and 2 mg midazolam)
Study: 19155895
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of oral sedation to intravenous sedation
Study: 8617132
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg four times a day for three days
Study: 1418064
Drug: Crystalline lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Crystalline lactulose (60 g/d for 30 days)
Study: 6319087
Drug: Oral digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral digoxin (0.25 mg/day)
Study: 22375947
Drug: Routine medical
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medical treatment (treatment as usual)
Study: 19540054
Drug: Treatment plans
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment plans meeting dose-volume constraints (V30<=80%, V40<=65%, V50<=55%, V60<=40%, V65<=30%, V70<=15%, V75<=3%)
Study: 10426891
Drug: Doxepin/TAC cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin/TAC cream (0.025% triamcinolone acetonide)
Study: 10426891
Drug: Doxepin cream
Normalized name: doxepin Topical Cream
DrugBank: Doxepin (DB01142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxepin cream (5% doxepin hydrochloride)
Study: 7547092
Drug: Tenidap sodium
Normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap sodium 120 mg day‐1
Study: 2158440
Drug: ZK 95962
Normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZK 95962 (20 micrograms/kg body weight, 2 injections, 10 min apart)
Study: 24211163
Drug: Dasatinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (100 mg orally once daily) plus docetaxel (75 mg/m² intravenously every 3 weeks, plus oral prednisone 5 mg twice daily)
Study: 24211163
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus docetaxel (75 mg/m² intravenously every 3 weeks, plus oral prednisone 5 mg twice daily)
Study: 24211163
Drug: Dasatinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (100 mg orally once daily) plus docetaxel
Study: 21430254
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of L-essential amino acids (EAA)
Study: 21430254
Drug: rapamycin (mTORC1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rapamycin (mTORC1 inhibitor) prior to EAA ingestion
Study: 31838589
Drug: PATCH (motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: PATCH (motivational enhancement intervention)
Study: 24783925
Drug: Jianpi suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jianpi suppository
Study: 23240940
Drug: Intranasal reduced
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal reduced glutathione (in)GSH
Study: 17092412
Drug: Ulinastatin plus
Normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin plus thymosin-alpha1 on the base of regular therapy for 1 week
Study: 12872390
Drug: Combined medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined medicine (CAL and western medicine)
Study: 12872390
Drug: CAL (composite
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAL (composite agastache lotion)
Study: 1762283
Drug: Verapamil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (20 patients), daily dose 60‐120 mg, mean 80 mg
Study: 1762283
Drug: Propranolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (20 patients), daily dose 120‐180 mg, mean 140 mg
Study: 7050868
Drug: Gentamicin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (2.5 mg/kg q6h)
Study: 7050868
Drug: Colistin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin (1 mg/kg q6h)
Study: 4026058
Drug: HFCWO at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFCWO at 5 Hz with 20 ml tidal volume (Series B)
Study: 4026058
Drug: HFCWO at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFCWO at 5 Hz with 40 ml tidal volume (Series C)
Study: 31197507
Drug: Juçara freeze-dried
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juçara freeze-dried pulp (5 g)
Study: 31197507
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 g)
Study: 10609975
Drug: MTT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTT with contingency contracts using monetary reinforcers targeting abstinence from illicit drug and alcohol use
Study: 16272751
Drug: Landiolol hydrochloride
Normalized name: Landiolol Hydrochloride
DrugBank: Landiolol (DB12212)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Landiolol hydrochloride (low dose: 0.03 mg/kg/min for 1 min loading, then 0.01 mg/kg/min for 10 min continuous)
Study: 16272751
Drug: Landiolol hydrochloride
Normalized name: Landiolol Hydrochloride
DrugBank: Landiolol (DB12212)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Landiolol hydrochloride (medium dose: 0.06 mg/kg/min for 1 min loading, then 0.02 mg/kg/min for 10 min continuous)
Study: 11579113
Drug: FEC (fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC (fluorouracil, epirubicin, and cyclophosphamide) chemotherapy, six cycles
Study: 1297554
Drug: Cervical collar
Normalized name: Cervical Collar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical collar therapy
Study: 9089428
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg once daily for a maximum of 10 weeks)
Study: 9089428
Drug: Lisinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10 mg once daily for a maximum of 10 weeks)
Study: 9089428
Drug: Metolazone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metolazone (1 mg once daily for a maximum of 10 weeks)
Study: 8404433
Drug: Acipimox (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (250 mg three times a day)
Study: 3544188
Drug: Carbenoxolone/antacid/alginate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone/antacid/alginate preparation (Pyrogastrone)
Study: 3544188
Drug: Antacid/alginate alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid/alginate alone (Control)
Study: 28853967
Drug: Monopolar RF
Normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monopolar RF device treatment (4 once-a-week sessions)
Study: 27039080
Drug: Rosuvastatin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin at 20 mg/day
Study: 27039080
Drug: Ezetimibe at
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe at 10 mg/day
Study: 27039080
Drug: Colestimide at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestimide at 3.62 g/day
Study: 10233878
Drug: combined decontamination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined decontamination medication
Study: 8912751
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide inhalation at 25 ppm
Study: 29698250
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion (5 mg/kg)
Study: 27154174
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg co-administered with vismodegib 150 mg QD for 7 days
Study: 27154174
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg co-administered with vismodegib 150 mg QD for 7 days
Study: 27154174
Drug: Fluconazole 400
Normalized name: fluconazole 400 MG in 200 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 400 mg co-administered with vismodegib 150 mg QD for 7 days
Study: 27154174
Drug: Control arm:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control arm: Vismodegib 150 mg QD for 7 days
Study: 23402387
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not on treatment)
Study: 15319760
Drug: Non-Spinal Manipulation
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Spinal Manipulation Treatment (N-SMT)
Study: 9234829
Drug: Cicletanine 100
Normalized name: cicletanine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 100 mg orally daily for 1 week
Study: 8270925
Drug: Vigabatrin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (1 g twice daily for six weeks, followed by 1.5 g twice daily for a further six weeks)
Study: 25048345
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ECG variables
Study: 22203755
Drug: Olaparib 200
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 200 mg twice per day
Study: 22203755
Drug: Olaparib 400
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 400 mg twice per day
Study: 22203755
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) 50 mg/m² intravenously every 28 days
Study: 20729336
Drug: Daily assessments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily assessments of positive affect (PA) and relatedness needs satisfaction (RNS) in Study 4
Study: 18611273
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus a platinum compound
Study: 8863239
Drug: Conservative, delayed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative, delayed surgery after intensive chemotherapy with or without radiotherapy
Study: 8863239
Drug: Additional chemotherapy
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional chemotherapy and late exenteration, prostatectomy, or biopsy for patients with relapse or residual disease
Study: 8863239
Drug: Gross primary
Normalized name: Ostericum grosseserratum root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gross primary excision, local radiotherapy, and vincristine and actinomycin therapy for group IIA tumors
Study: 1651360
Drug: CMV-specific intravenous
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV-specific intravenous immunoglobulin (IVIG) 200 mg/kg on days 8 and 6 before transplant, the day after transplant, weekly for the first month, and then every 2 weeks to complete 10 doses
Study: 30730425
Drug: Whole body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole body vibration therapy
Study: 24655598
Drug: No-drug control
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-drug control
Study: 24507823
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml wine
Study: 24507823
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml wine
Study: 24507823
Drug: 300 ml
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ml wine
Study: 24507823
Drug: Cut-off value
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cut-off value of 8.84 μg/mg creatinine
Study: 22853848
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg/Amlodipine 5 mg (I150/A5)
Study: 22853848
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg/Amlodipine 10 mg (I150/A10)
Study: 17158003
Drug: Hormone Therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone Therapy (HT) users
Study: 12510212
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg transdermal estradiol
Study: 12510212
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg transdermal estradiol
Study: 350397
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with bacillus Calmette‐Guérin
Study: 350397
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with Corynebacterium parvum (C. parvum)
Study: 350397
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (MOCA)
Study: 31443893
Drug: Mindfulness practice
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness practice time without minimum treatment dose requirement
Study: 25817373
Drug: Low-dose adenovirus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose adenovirus type-5 vector-based Ebola vaccine
Study: 25817373
Drug: High-dose adenovirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adenovirus type-5 vector-based Ebola vaccine
Study: 27852684
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day resveratrol (resVida)
Study: 19037040
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 800 mcg
Study: 23102797
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol 800 mcg
Study: 16925756
Drug: Adjuvant luteinizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant luteinizing hormone-releasing hormone (LHRH) agonist in Study 1
Study: 16925756
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist monotherapy or combined androgen blockade in Study 2
Study: 14517191
Drug: Mibefradil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil (100 mg oral dose)
Study: 1410164
Drug: Nicotine (0.4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (0.4, 0.6, and 0.8 mg subcutaneously)
Study: 23195963
Drug: Oral enteric
Normalized name: Ascriptin Enteric Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enteric insulin 50 U
Study: 23195963
Drug: Oral enteric
Normalized name: Ascriptin Enteric Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enteric insulin 100 U
Study: 23195963
Drug: Oral enteric
Normalized name: Ascriptin Enteric Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enteric insulin 200 U
Study: 23195963
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin 6 U
Study: 15385809
Drug: Basiliximab (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (two 20-mg doses on days 0 and 4) + Tacrolimus (0.15 mg/kg/day; target trough levels 10-15 ng/mL)
Study: 9714353
Drug: Larsen's (L)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larsen's (L) radiological scoring method
Study: 8790563
Drug: Pre-S vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-S vaccine (12 micrograms, 24 micrograms, 48 micrograms)
Study: 8790563
Drug: Pre-S vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-S vaccine (48 micrograms)
Study: 8790563
Drug: Pre-S vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-S vaccine (any dose)
Study: 24267730
Drug: Everolimus (EVE)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus (EVE) 10 mg/d plus Exemestane (EXE) 25 mg/d
Study: 21603651
Drug: ADVAX 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADVAX 0.2 mg via electroporation
Study: 21603651
Drug: ADVAX 1
Normalized name: Tdvax
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADVAX 1 mg via electroporation
Study: 21603651
Drug: ADVAX 4
Normalized name: diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 4 UNT/ML [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADVAX 4 mg via electroporation
Study: 21603651
Drug: ADVAX 4
Normalized name: diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 4 UNT/ML [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADVAX 4 mg via standard intramuscular injection
Study: 21603651
Drug: ADVAX 4
Normalized name: diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 4 UNT/ML [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADVAX 4 mg via electroporation (third vaccination at week 36)
Study: 15064942
Drug: oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral iron
Study: 11996476
Drug: Vinorelbine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 20 mg/m2 (or 15 mg/m2 if prior pelvic radiotherapy) combined with estramustine phosphate (EMP) at 280 mg orally tds for 3 days, then every other week after 8 weeks
Study: 8085286
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody assays (MAAs)
Study: 8085286
Drug: MAA values
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAA values of 10, 15, and 20 micrograms/ml
Study: 23057495
Drug: S-1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 plus oxaliplatin (oxaliplatin 50 mg/m² on days 1, 8, 22, and 29; S-1 80 mg/m² per day on days 1-14 and 22-35)
Study: 15160576
Drug: Non-adherent gauze
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adherent gauze plus compression therapy
Study: 11176329
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution (ORS) with smectite
Study: 9847464
Drug: Electron beam
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electron beam treatment (9/12 MeV and 12 MeV) to chest wall and drainage area, 50 Gy over 5 weeks at 2 Gy per fraction.
Study: 9847464
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (Cyclophosphamide, Methotrexate, and 5-Fluorouracil) for pre-menopausal patients with axillary node involvement.
Study: 9847464
Drug: Adjuvant tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant tamoxifen 10 mg bid for post-menopausal patients.
Study: 9847464
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (Electron beam)
Study: 2643331
Drug: Acetazolamide tablets
Normalized name: Acetazolamide Tablets
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide tablets (500 mg)
Study: 2643331
Drug: Methazolamide tablets
Normalized name: Methazolamide Tablets
DrugBank: Methazolamide (DB00703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methazolamide tablets
Study: 2643331
Drug: Previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment with carbonic anhydrase inhibitors
Study: 788494
Drug: Zinc supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplemented formula (4 mg/liter of zinc)
Study: 27883201
Drug: VIA-2291 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIA-2291 (25 mg, 50 mg, 100 mg)